SCHEMBL25857845

SCHEMBL25857845

CCCCn1ncnc1C(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ MPO P05164 2/20 0.34
▸ SLC9A1 P19634 2/20 0.34
▸ ADRA1D P25100 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ ADRA1B P35368 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TLR8 Q9NR97 2/20 0.33
▸ DGAT1 O75907 1/20 0.32
▸ NR1H3 Q13133 1/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ CYP1A2 P05177 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ GRM2 Q14416 1/20 0.31
▸ TSHR P16473 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ CNR1 P21554 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19219033 0.89 ADORA2A (0.32) POLBSLC9A1ADRA1DADRA1AADRA1B
SCHEMBL25744941 0.84 — —
SCHEMBL12410848 0.80 XDH (0.32) SMN1; SMN2
SCHEMBL5319147 0.80 TSHR (0.31) TSHR
SCHEMBL25744942 0.79 — —
SCHEMBL10308909 0.79 SMN1; SMN2 (0.33) SMN1; SMN2CYP1A2LMNA
SCHEMBL25619102 0.79 SMN1; SMN2 (0.33) ALDH1A1SMN1; SMN2
SCHEMBL5324893 0.77 TSHR (0.41) SMN1; SMN2TSHR
SCHEMBL25619100 0.76 UBE2M (0.39) —
SCHEMBL25744940 0.76 SMN1; SMN2 (0.31) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 — — US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 KMT2A 2634/4885ALDH1A1 164/4885POLB 4678/4885
US-11702422-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 KMT2A 2634/4885ALDH1A1 164/4885POLB 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback